TY - JOUR
T1 - Circulating GPIHBP1 levels and microvascular complications in patients with type 2 diabetes
T2 - A cross-sectional study
AU - Kurooka, Naoko
AU - Eguchi, Jun
AU - Murakami, Kazutoshi
AU - Kamei, Shinji
AU - Kikutsuji, Toru
AU - Sasaki, Sakiko
AU - Seki, Akiho
AU - Yamaguchi, Satoshi
AU - Nojima, Ichiro
AU - Watanabe, Mayu
AU - Higuchi, Chigusa
AU - Katayama, Akihiro
AU - Uchida, Haruhito A.
AU - Nakatsuka, Atsuko
AU - Shikata, Kenichi
AU - Wada, Jun
N1 - Funding Information:
Jun Wada receives speaker honoraria from Astra Zeneca, Daiichi Sankyo, Novartis, Novo Nordisk Pharma, and Tanabe Mitsubishi, and receives grant support from Astellas, Baxter, Bayer, Chugai, Dainippon Sumitomo, Kyowa Kirin, Novo Nordisk Pharma, Ono, Otsuka, Tanabe Mitsubishi, and Teijin. The other authors declare no competing interests with respect to this paper.
Funding Information:
Funding: This work was supported by a Grant-in-Aid for Young Scientists ( 19K17984 ), a Grant-in-Aid for Scientific Research (B ) ( 19H03675 ), and the Japan Agency for Medical Research and Development (AMED, grant no: 17ek0210095h0001 , 20ek0109445h0001 ). We are grateful to Mr. Kazuya Miyashita for helpful suggestions.
Publisher Copyright:
© 2022 National Lipid Association
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background: Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) plays a crucial role in lipolytic processing. Previous studies have shown that GPIHBP1 mutations cause severe hypertriglyceridemia and that serum GPIHBP1 levels are marginally higher in patients with coronary heart disease; however, the role of GPIHBP1 in type 2 diabetes mellitus (T2DM) remains unknown. Objective: We investigated the association between circulating GPIHBP1 levels and the prevalence of microvascular complications in T2DM. Methods: A total of 237 subjects with T2DM and 235 non-diabetic control subjects were enrolled in this study. Their serum GPIHBP1 levels were evaluated using ELISA assays. Results: Circulating GPIHBP1 levels were higher in patients with T2DM (952.7 pg/mL [761.3-1234.6], p < 0.0001) than in non-diabetic subjects (700.6 [570.8-829.6]), but did not differ in T2DM patients with or without hypertriglyceridemia. Serum GPIHBP1 levels were significantly higher in patients with T2DM with diabetic retinopathy (DR), diabetic nephropathy (DN), and microvascular complications than in those without these complications. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses revealed that the presence of microvascular complications, but not macrovascular complications, was independently associated with serum GPIHBP1 levels, which could predict the presence of diabetic microvascular complications. Conclusions: Elevated GPIHBP1 levels are associated with microvascular complications in T2DM and may help to predict their progression.
AB - Background: Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1) plays a crucial role in lipolytic processing. Previous studies have shown that GPIHBP1 mutations cause severe hypertriglyceridemia and that serum GPIHBP1 levels are marginally higher in patients with coronary heart disease; however, the role of GPIHBP1 in type 2 diabetes mellitus (T2DM) remains unknown. Objective: We investigated the association between circulating GPIHBP1 levels and the prevalence of microvascular complications in T2DM. Methods: A total of 237 subjects with T2DM and 235 non-diabetic control subjects were enrolled in this study. Their serum GPIHBP1 levels were evaluated using ELISA assays. Results: Circulating GPIHBP1 levels were higher in patients with T2DM (952.7 pg/mL [761.3-1234.6], p < 0.0001) than in non-diabetic subjects (700.6 [570.8-829.6]), but did not differ in T2DM patients with or without hypertriglyceridemia. Serum GPIHBP1 levels were significantly higher in patients with T2DM with diabetic retinopathy (DR), diabetic nephropathy (DN), and microvascular complications than in those without these complications. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses revealed that the presence of microvascular complications, but not macrovascular complications, was independently associated with serum GPIHBP1 levels, which could predict the presence of diabetic microvascular complications. Conclusions: Elevated GPIHBP1 levels are associated with microvascular complications in T2DM and may help to predict their progression.
KW - Diabetes mellitus
KW - Diabetic nephropathy
KW - Diabetic retinopathy
KW - Glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 (GPIHBP1)
KW - Hypertriglyceridemia
UR - http://www.scopus.com/inward/record.url?scp=85123726270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123726270&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2022.01.006
DO - 10.1016/j.jacl.2022.01.006
M3 - Article
C2 - 35101360
AN - SCOPUS:85123726270
SN - 1933-2874
VL - 16
SP - 237
EP - 245
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 2
ER -
